MTLN loss has been associated with changes in mitochondrial calcium [7], ER contacts [18], mitochondrial superoxide [7,18], fatty acid oxidation [9,12,19], retrograde JUN signaling [65], and lipid metabolism [10,16,19], all with the potential to influence cancer progression or sensitivity to anti-cancer drugs [94,95,96,97,98]. The gene discussed is JUN; the disease is cancer.